← All trials
NCT05238116
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 14, 2022
- Primary completion
- Oct 31, 2023
- Completion date
- Nov 30, 2023
- First posted
- Feb 14, 2022
- Last posted
- Sep 27, 2022
- Enrollment
- 123
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Pulmocide LtdLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.